Antifungal Therapy Fast Tracked, Granted QDIP Status by FDA
Cidara Therapeutics announced that the Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) with Fast Track status to its investigational antifungal therapy CD101 IV for the treatment of candidemia and invasive candidiasis.
CD101 IV, a novel long-acting agent, is being developed for the treatment of systemic Candida infections, including candidemia and related cases of invasive candidiasis.
The company plans to file an investigational new drug application (IND) as well as initiate a Phase 1 clinical trial for CD101 IV in the second half of 2015.
For more information visit Cidara.com.